Cooper Companies, Inc.

Most Recent

  • uploads///Vision Care
    Company & Industry Overviews

    JNJ’s Vision Care Segment Witnessed Solid Growth in Q1 2018

    In June, the FDA approved Johnson & Johnson’s iDESIGN Refractive Studio, which can be utilized for customized LASIK treatment.

    By Daniel Collins
  • uploads///Alcon
    Company & Industry Overviews

    How Novartis’s Alcon Performed in 4Q17 and Fiscal 2017

    In 4Q17, Novartis’s (NVS) subsidiary Alcon generated revenues of $1.56 billion compared to $1.44 billion in 4Q16, which reflected ~8% growth on a year-over-year (or YoY) basis and ~2% growth quarter-over-quarter.

    By Daniel Collins
  • uploads///blood _
    Company & Industry Overviews

    Analysts’ Recommendations for Haemonetics and Peers in March 2018

    In its fiscal 3Q18, which ended on December 31, 2017, Haemonetics (HAE) reported revenue of close to $234 million.

    By Margaret Patrick
  • uploads///Vision care
    Company & Industry Overviews

    Inside Johnson & Johnson’s Vision Care Performance in 3Q17

    In 3Q17, JNJ vision care generated revenues of $1.1 billion, which reflected a ~48% YoY (year-over-year) rise and a 3% QoQ (quarter-over-quarter) rise.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Novartis Expects to Restore Alcon’s Profitability in the Future

    Novartis (NVS) has focused its efforts on improving its customer service levels and entering into lucrative partnering deals to boost profitability for its Alcon business.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Will Novartis’s Alcon Business See Growth in 2017?

    Novartis (NVS) expects its Alcon business to report low-single-digit revenue growth in 2017.

    By Margaret Patrick
  • Company & Industry Overviews

    Stellar YTD 2016 for MFS Massachusetts Investors Growth Stock Fund

    The MFS Massachusetts Investors Growth Stock Fund – Class A (MIGFX) is the only fund in this review that has outperformed the passively managed SPDR S&P 500 ETF Trust (SPY).

    By David Ashworth
  • uploads///gks COO
    Earnings Report

    Cooper Companies Shows Strong Relative Earnings Compared to Peers

    The PowerShares DWA Healthcare Momentum Portfolio (PTH) invests 4.54% of its holdings in Cooper.

    By Gabriel Kane
  • uploads///gks coo
    Earnings Report

    Cooper Companies Reported Mixed 2Q15 Results

    Cooper Companies (COO) is a $7.33 billion global medical device company. The company has two business units, CooperVision and CooperSurgical.

    By Gabriel Kane
  • uploads///COO
    Fund Managers

    Lone Pine Adds New Stake in The Cooper Companies

    Cooper’s results for fiscal 1Q15 beat the EPS estimates, but it missed on revenue. Cooper’s revenue grew 10% year-over-year to $445.2 million.

    By Samantha Nielson
  • uploads///Lone Pine
    Fund Managers

    Lone Pine Capital Holdings Traded During 4Q14

    Tiger cub Stephen Mandel’s Lone Pine Capital’s US long portfolio saw a slight fall from $25.5 billion in 3Q14 to $23.8 billion in 4Q14.

    By Samantha Nielson
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.